Insulet (MEX:PODD) Cyclically Adjusted Revenue per Share: MXN432.56 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PODD Insulet Corp MEX:PODD
75 GF Score
Price MXN2,780.00
GF Value MXN6,970.09
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Cyclically Adjusted Revenue per Share?

Insulet MEX:PODD 75 Cyclically Adjusted Revenue per Share is MXN432.56 as of Mar. 2026. GuruFocus rates MEX:PODD with a GF Score™ of 75/100 and a GF Value™ of MXN6,970.09 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Insulet's adjusted revenue per share for the three months ended in Mar. 2026 was MXN195.657. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN432.56 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Insulet's average Cyclically Adjusted Revenue Growth Rate was 24.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 20.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Insulet was 21.00% per year. The lowest was 3.70% per year. And the median was 19.80% per year.

As of today (2026-07-15), Insulet's current stock price is MXN2780.00. Insulet's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN432.56. Insulet's Cyclically Adjusted PS Ratio of today is 6.43.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 7.03. And the median was 18.30.


Insulet  (MEX:PODD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Insulet's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2780.00/432.56
=6.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Insulet was 39.07. The lowest was 7.03. And the median was 18.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Insulet Cyclically Adjusted Revenue per Share Related Terms


Insulet Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Insulet's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Cyclically Adjusted Revenue per Share Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.94 217.84 196.24 316.04 411.51

Insulet Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 331.32 321.19 361.85 411.51 432.56

MEX:PODD vs GMED, PEN, BRKR: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Insulet's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Insulet's Cyclically Adjusted PS Ratio falls into.


MEX:PODD
75GF Score
Insulet Corp MEX:PODD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insulet's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=195.657/330.2130*330.2130
=195.657

Current CPI (Mar. 2026) = 330.2130.

Insulet Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 28.237 241.018 38.687
201609 31.991 241.428 43.756
201612 37.177 241.432 50.848
201703 33.195 243.801 44.961
201706 34.220 244.955 46.130
201709 38.037 246.819 50.889
201712 44.026 246.524 58.972
201803 38.389 249.554 50.797
201806 41.502 251.989 54.385
201809 46.215 252.439 60.453
201812 47.826 251.233 62.861
201903 50.630 254.202 65.769
201906 55.328 256.143 71.327
201909 60.839 256.759 78.244
201912 61.677 256.974 79.255
202003 73.830 258.115 94.453
202006 79.652 257.797 102.027
202009 77.352 260.280 98.135
202012 73.077 260.474 92.643
202103 78.007 264.877 97.249
202106 78.554 271.696 95.473
202109 81.399 274.310 97.988
202112 86.935 278.802 102.966
202203 84.195 287.504 96.702
202206 86.847 296.311 96.783
202209 98.752 296.808 109.866
202212 100.650 296.797 111.982
202303 92.084 301.836 100.741
202306 96.911 305.109 104.885
202309 102.374 307.789 109.832
202312 102.774 306.746 110.637
202403 99.410 312.332 105.101
202406 121.262 314.175 127.452
202409 144.820 315.301 151.669
202412 168.227 315.605 176.014
202503 157.071 319.799 162.186
202506 172.989 322.561 177.093
202509 183.362 324.800 186.418
202512 199.707 324.054 203.503
202603 195.657 330.213 195.657

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN432.56 mean?
Insulet (MEX:PODD) has a Cyclically Adjusted Revenue per Share of MXN432.56 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insulet and its competitors.
Is Insulet's Cyclically Adjusted Revenue per Share too high?
Insulet's current Cyclically Adjusted Revenue per Share is MXN432.56. Overall, Insulet has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Cyclically Adjusted Revenue per Share compare to GMED and PEN?
Insulet's Cyclically Adjusted Revenue per Share of MXN432.56 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insulet and its competitors. Insulet's current Cyclically Adjusted Revenue per Share is MXN432.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MEX:PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN6,970.09, compared to a current price of MXN2,780.00 — trading 60.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN432.56. Insulet's overall GF Score™ is 75/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Insulet (MEX:PODD), the current Cyclically Adjusted Revenue per Share is MXN432.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (MEX:PODD) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of MXN2,780.00 is trading 60.1% below its estimated GF Value™ of MXN6,970.09. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for MEX:PODD:

  • Cyclically Adjusted Revenue per Share: MXN432.56
  • GF Value™: MXN6,970.09 vs. price of MXN2,780.00 (60.1% below fair value)
  • GF Score™: 75/100

No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
75GF Score

Get the complete analysis for MEX:PODD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,780.00
Price
MXN6,970.09
GF Value